Abstract
Sphingolipids are structurally and functionally diverse molecules with significant physiologic functions and are found associated with cellular membranes and plasma lipoproteins. The cellular and plasma concentrations of sphingolipids are altered in several metabolic disorders and may serve as prognostic and diagnostic markers. Here we discuss various sphingolipid transport mechanisms and highlight how changes in cellular and plasma sphingolipid levels contribute to cardiovascular disease, obesity, diabetes, insulin resistance, and nonalcoholic fatty liver disease (NAFLD). Understanding of the mechanisms involved in intracellular transport, secretion, and extracellular transport may provide novel information that might be amenable to therapeutic targeting for the treatment of various metabolic disorders.
Deregulation of plasma sphingolipids is implicated in many metabolic disorders and they are emerging as biomarkers and prognostic indicators.
The importance of plasma sphingolipids and recent technological advances in lipidomics has spurred investigation into sphingolipid transport mechanisms and the effects of specific sphingolipid species in disease.
Identification of proteins involved in sphingolipid efflux and transport may provide additional therapeutic targets for metabolic disorders.